NeuroMetrix, Inc. (NURO) News
Filter NURO News Items
NURO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest NURO News From Around the Web
Below are the latest news stories about NeuroMetrix Inc that investors may wish to consider to help them evaluate NURO as an investment opportunity.
NeuroMetrix''s Quell Neuromodulator Will Be Tested In Long COVID-19 SyndromeNeuroMetrix Inc''s (NASDAQ: NURO ) Quell wearable neuromodulation technology will be evaluated for fibromyalgia-like syndrome in individuals with post-acute COVID-19 syndrome (PACS, or "long COVID"). Quell is an advanced, non-invasive neuromodulation technology covered by 22 U.S. utility patents and numerous … Full story available on Benzinga.com |
NeuroMetrix's Quell Neuromodulator Will Be Tested In Long COVID-19 SyndromeNeuroMetrix Inc's (NASDAQ: NURO) Quell wearable neuromodulation technology will be evaluated for fibromyalgia-like syndrome in individuals with post-acute COVID-19 syndrome (PACS, or "long COVID"). Quell is an advanced, non-invasive neuromodulation technology covered by 22 U.S. utility patents and numerous international patents. It is the only wearable neuromodulator enabled by a proprietary microchip that provides precise, high-power nerve stimulation in a form factor the size of a credit card. |
NeuroMetrix Reports that Quell® Wearable Neuromodulator to be Evaluated in Post-Acute COVID-19 SyndromeWOBURN, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell wearable neuromodulation technology will be evaluated for treatment of a fibromyalgia-like syndrome in individuals with post-acute COVID-19 syndrome (PACS, or "long COVID"). The trial will be conducted at the Baylor College of Medicine in collaboration with the National Science Foundation (NSF) funded Center to Stream Healthcare In Place (C2SHIP). The principal investigator is Dr. Bij |
NeuroMetrix reports Q4 results (NASDAQ:NURO)NeuroMetrix press release (NURO): Q4 net loss of $1MRevenue of $1.82M (+0.6% Y/Y). |
NeuroMetrix, Inc.''s (NURO) CEO Dr. Shai Gozani on Q4 2021 Results - Earnings Call TranscriptNo summary available. |
NeuroMetrix Reports Q4 and Full Year 2021 Financial ResultsWOBURN, Mass., Jan. 27, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2021. The Company's mission is to reduce the impact of neurological disorders and pain syndromes on individuals and on population health through innovative non-invasive medical devices. Highlights: Q4 revenue of $1.8 million was up slightly from Q4 2020. Full year revenue of $8.3 million increased by 11.9% from the pri |
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2021 Financial Results Conference CallWOBURN, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 fourth quarter and full year financial results before the opening of the market on January 27, 2022. The Company will host a conference call at 8:00 a.m., Eastern Time on January 27, 2022 to discuss its financial results as well as business developments affecting the Company. The conference call may be accessed in the United States by dialing 844-787-0799 and using th |
BLNK Stock: 9 Things for Blink Charging Investors to Know About the GM DealBlink Charging (BLNK) stock is getting a boost on Tuesday from a deal with General Motors (GM) for its electric vehicle (EV) chargers. |
Market Update: Why Are Stocks Down Tuesday?It's time for a market update and we're diving into why stocks are down on Tuesday and there's plenty of reasons for today's dip. |
NURO Stock: Why NeuroMetrix Investors Are Feeling No Pain TodayNeuroMetrix (NURO) stock is rocketing higher on Tuesday thanks to the FDA granting it Breakthrough Designation for one of its devices. |